HilleVax to Participate in November Investor Conferences
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, a clinical-stage biopharmaceutical company, will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, a clinical-stage biopharmaceutical company, will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference. Key discussions will focus on HIL-214, an investigational virus-like particle vaccine aimed at preventing moderate-to-severe norovirus-related gastroenteritis, and its ongoing Phase 2b clinical trial, NEST-IN1. Events are scheduled for November 14 and November 16, 2022, featuring CEO Robert Hershberg.
Details
News Market Reaction – HLVX
The recorded move for HLVX in the trading session of this news was -7.90%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that it will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference. HIL-214, HilleVax’s investigational virus-like particle (VLP) based vaccine for the prevention of moderate-to-severe norovirus-related acute gastroenteritis, and the related ongoing Phase 2b clinical trial NEST-IN1 will be topics of discussion at both events.
| Guggenheim fireside chat details: | ||
| Date: Time: Moderator: HilleVax Participant: | Monday, November 14, 2022 3:55 – 4:20 p.m. Eastern Daylight Time (EDT) Seamus Fernandez Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer | |
| Please contact your Guggenheim representative to access the session | ||
| Stifel presentation details: Date: Time: Moderator: HilleVax Participant: Webcast Link: | Wednesday, November 16, 2022 8:35 – 9:05 a.m. Eastern Daylight Time (EDT) Stephen Willey Robert Hershberg, M.D., Ph.D., Chairman and Chief Executive Officer https://wsw.com/webcast/stifel74/hlvx/2126052 | |
About HilleVax
HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Its initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. Globally, norovirus is estimated to result in over approximately 700 million cases of AGE and 200,000 deaths per year, resulting in over
Contact:
Shane Maltbie
IR@hillevax.com
+1-617-213-5054
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.